Company: AGIO
Filing Date: 2025-10-30
Form Type: 10-Q
Source: 0001439222-25-000116
Chunk: 176

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-10-30
Form: 10-Q
Item: Part I, Item 8
Chunk 176
---
 Instruments - Credit Losses, to determine if the impairment is credit-related or noncredit-related. Credit-related impairment is recognized as an allowance on the condensed consolidated balance sheets with a corresponding adjustment to earnings, and noncredit-related impairment is recognized in other comprehensive income, net of taxes. Realized gains and losses are included in investment income on a specific-identification basis. There were no material realized gains or losses on marketable securities for the three and nine months ended September 30, 2025 or 2024.Marketable securities at September 30, 2025 consisted of the following:(In thousands)AmortizedCostUnrealizedGainsUnrealizedLossesFairValueCurrent:Certificates of deposit$2,672 $2 $— $2,674 U.S. Treasuries133,848 172 (31)133,989 Government securities137,907 83 (30)137,960 Corporate debt securities584,904 683 (60)585,527 Total current859,331 940 (121)860,150 Non-current:U.S. Treasuries154,462 743 (7)155,198 Government securities38,472 31 (8)38,495 Corporate debt securities110,175 488 (15)110,648 Total non-current303,109 1,262 (30)304,341 Total marketable securities$1,162,440 $2,202 $(151)$1,164,491 

10

Marketable securities at December 31, 2024 consisted of the following:(In thousands)AmortizedCostUnrealizedGainsUnrealizedLossesFairValueCurrent:Certificates of deposit$10,374 $11 $— $10,385 U.S. Treasuries173,465 153 (27)173,591 Government securities167,970 103 (75)167,998 Corporate debt securities465,427 321 (259)465,489 Total current817,236 588 (361)817,463 Non-current:U.S. Treasuries107,725 106 (303)107,528 Government securities112,175 3 (469)111,709 Corporate debt securities420,166 181 (1,263)419,084 Total non-current640,066 290 (2,035